Advertisement

Psoriatic Arthritis

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/30/2023

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/30/2023
Treatment
Treatment
FDA Approves First Treatment for Active Psoriatic Arthritis in Pediatric Patients
08/23/2022
The US Food and Drug Administration has approved a new treatment for pediatric patients with active psoriatic arthritis.
08/23/2022
Medication prescribing
Medication prescribing
FDA Approves New Treatment Option for Patients With Psoriatic Arthritis
01/24/2022
The US Food and Drug Administration has approved the drug based on the results from the KEEPsAKE-1 and KEEPsAKE-2 randomized, placebo-controlled studies.
01/24/2022
FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
FDA ALERT
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015